1, and it is the dominant strain circulating in the U.S., accounting for roughly 3 in 4 new Covid cases, according to FDA briefing documents released earlier this week. It’s different from a ...

Novavax expects to be ready for the commercial delivery of the 2025-2026 COVID-19 vaccine formula in the U.S. this fall in partnership with Sanofi, pending strain recommendation at the FDA ...